Mukesh Verma, Ph.D.
Branch Chief, Methods and Technologies Branch

Photo of Mukesh Verma

Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E102, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)


  • Ph.D. - Host-virus Interaction
    Banaras Hindu University
  • M.Sc. - Biochemistry (Major) and Microbiology (Minor)
    Pantnagar University
  • B.Sc. - Biological Sciences
    Meerut University

Interest Areas

  • Biomarkers
  • Epigenetics
  • Epidemiology Technologies
  • Proteomics
  • MicroRNA
  • Methylation
  • Mitochondria
  • Nanotechnology
  • Risk Assessment
  • Susceptibility Factors
  • Systems Genetics
  • Metabolomics


Dr. Verma is Chief of the Epidemiology and Genomics Research Program's (EGRP) Methods and Technologies Branch (MTB), and oversees its research portfolio and initiatives that focus on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility.

He is responsible for stimulating EGRP-funded research on epigenetic approaches in cancer epidemiology and has been instrumental in developing epigenetics research for NIH as a whole. Dr. Verma helped to develop a Request for Applications (RFA) on Environmental Influences on Epigenetics with the National Institute of Environmental Health Sciences (NIEHS) and represents the Division of Cancer Control and Population Sciences (DCCPS), in NIH's Roadmap Initiative on EpigeneticsExternal Web Site Policy. He helped develop an RFA on Comparative Systems Genetics of Cancer with NCI's Division of Cancer Biology (DCB), and is known within the extramural research community as an EGRP Program Director for Program Announcements (PAs) on Small Grants for Cancer Epidemiology and Pilot Studies in Pancreatic Cancer. He also organized a workshop to explore developing a concept for a research initiative on mitochondrial DNA and cancer epidemiology.

Dr. Verma was, and continues to be, a co-Program Director for initiatives in gene-environment interactions in cancer etiology, including the Breast and Prostate Cancer and Hormone-Related Variants Cohort Consortium (BPC3), which is a collaborative project to pool data and biospecimens from a group of large prospective cancer epidemiology cohorts.

Dr. Verma joined EGRP as a Program Director in 2004. In 2005, he was appointed Acting Chief of EGRP's former Analytic Epidemiology Research Branch (AERB). When EGRP reorganized in 2007, he was appointed Acting Chief of MTB and of the former Host Susceptibility Factors Branch (HSFB), for which he served as Acting Chief through 2008. Before joining EGRP, he was a Program Director in NCI's Division of Cancer Prevention (DCP), where he worked in the areas of biomarkers, early detection, risk assessment, and prevention. He also was Coordinator of DCP's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. He was on the faculty in the Biochemistry Department of Georgetown University before joining NIH.


Verma, M., Agarwal, N., and Verma, M. Epigenetics and animal models: applications in cancer control and treatment. In: Verma, A. and Singh, A, eds. Animal Biotechnology. Boston, MA: Elsevier Inc. 2014; 57-72.

Verma, M., Agarwal, N., and Verma, M. Mitochondria DNA in early cancer diagnosis and screening (Chapter 6). In: Barh D, Carpi A, Verma M, and Gunduz M, eds. Cancer Biomarkers: Minimal and Noninvasive Early Diagnosis and Prognosis. CRC Press. 2014; 95-114.

Verma, M., Barh, D., Jain, N. Noninvasive early markers in lung cancer. (Chapter 10). In: Barh D, Carpi A, Verma M, and Gunduz M, eds. Cancer Biomarkers: Minimal and Noninvasive Early Diagnosis and Prognosis. CRC Press 2014; 415-431.

Verma, M., Rogers, S., Divi, R.L., Schully, S.D., Nelson, S., Su, L.1, Ross, S.A., Pilch, S., Winn, D.M., Khoury, M.J. Epigenetic Research in Cancer Epidemiology: Trends, Opportunities, and ChallengesExternal Web Site Policy. Cancer Epidemiology Biomarkers and Prevention. 2014; 23: 223-233.

Verma, M., Khoury, M. J., and Ioannidis, P.A. Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profilingExternal Web Site Policy. Cancer Epidemiology Biomarkers and Prevention. 2013; 22: 189-200.

Verma, M. Cancer control and prevention: nutrition and epigeneticsExternal Web Site Policy. Curr Opin Nutr Metab Care. 2013; 16: 376-384.

Verma, M. Nutracutical-gut microbiome interactions in human disease. In: Mahabir, Somdat, and Pathak, Yashwant, eds. Neutraceuticals and Health: Review of Human Evidence. NY: CRC Press. 2013; 243-252.

Vedham, V., Divi, R.L., Starks, V.L., Verma, M. Multiple infections and cancer: implications in epidemiologyExternal Web Site Policy. Technol Cancer Res Treat. 2014 Apr;13(2):177-94.

Zhang, Q., Verma, M., and Khare S. Epigenetic regulation of microRNA in colon cancer. In: Sarkar, F.H., ed. Epigenetics and Cancer. NY: Springer Press. 2013; 85-94.

Return to Top